Opinion statement
Hepatitis C viremia after liver transplantation for hepatitis C virus (HCV) liver disease is universal. Progressive HCV disease after transplantation is the leading cause of death, graft failure, and retransplantation. Whether to treat, with which agents, and timing of therapy are unanswered questions. Timing options include pretransplantation, prophylactic, posttransplantation preemptive, and post-transplantation recurrence-based therapy. The latter is most commonly utilized. There are little data for each of these, much less comparisons. Pegylated interferon-a has supplanted standard interferon-a due to increased efficacy and is generally used in combination with ribavirin (RBV). Efficacy is less than in nontransplant settings due to immunosuppression, an increased prevalence of genotype 1 HCV, patient comorbidities, and decreased functional status. Administration of HCV therapy to cirrhotic patients prior to transplantation may eradicate or suppress HCV and prevent or reduce severity of recurrence. Sustained virological response (SVR) as high as 50% was attained in genotypes 2 or 3 HCV. Comparison of preemptive and histology-based post-transplantation HCV therapy should be done, and more data will be available on pretransplantation therapy. Post-transplant patients are less tolerant of therapy, particularly RBV. SVR, the primary goal of therapy, likely halts disease progression, but only 20% to 30% of treated patients achieve SVR. Preemptive therapy early after transplantation may have advantages due to the potential to delay or blunt severity of graft infection and recurrent hepatitis. In posttransplant therapy, RBV toxicity is attenuated in relation to decreased renal function, and side effects of interferon are more prominent. An ongoing trial will assess preemptive therapy with treatment after histologic recurrence. Novel anti-HCV therapies such as protease and polymerase inhibitors are emerging. These must be tested with urgency in the transplant setting. Retransplantation for progressive HCV disease is more controversial due to poor outcomes, graft shortage, and disease recurrence.
Similar content being viewed by others
References and Recommended Reading
Charlton M: Recurrence of hepatitis C infection: Where are we now? Liver Transpl 2005, 11(Suppl 2):S57-S62.
Ercolani G, Grazi G, Ravaioli M, et al.: Histological recurrent hepatitis C after liver transplantation: outcome and role of retransplantation. Liver Transpl 2006, 12:1104–1111.
Neumann UP, Neuhaus P: Course and treatment of recurrent hepatitis C after liver transplantation. Minerva Gastroenterol Dietol 2004, 50:61–66.
Wiesner RH, Sorrell M, Villamil F: Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003, 9:S1-S9.
Burak KW, Kremers WK, Batts KP, et al.: Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002, 8:362–369.
Kato T, Yoshida H, Sadfar K, et al.: Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. Transplant Proc 2005, 37:1217–1219.
Strader DB, Wright T, Thomas DL, et al.: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147–1171.
Forns X, Garcia-Retortillo M, Serrano T, et al.: Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003, 39:389–396.
Everson GT, Trotter J, Forman L, et al.: Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255–262. Single-center experience notes a 50% SVR in decompensated genotype 2 and 3 HCV-infected patients treated with LADR. SVR was 13% and toxicity was increased in genotype 1 patients.
Crippin JS, McCashland T, Terrault N, et al.: A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002, 8:350–355.
Thomas RM, Brems JJ, Guzman-Hartman G, et al.: Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003, 9:905–915.
Everson GT: Treatment of hepatitis C in patients who have decompensated cirrhosis. Clin Liver Dis 2005, 9:473–486.
Forns X, Navasa M, Rodes J: Treatment of HCV infection in patients with advanced cirrhosis. Hepatology 2004, 40:498.
National Institutes of Health. Low accelerating dosage regimen (LADR) ancillary study of the adult to adult living donor liver transplantation study (A2ALL). Available at: www.nih-a2all.org. Accessed June 15, 2006.
Hepatitis C long-term treatment against cirrhosis study (HALT-C). Available at: www.haltctrial.org. Accessed June 15, 2006.
Study of long-term peg intron vs. colchicine in nonresponders (COPILOT). Available at: www.clinicaltrials. gov/ct/show/NCT00179413. Accessed June 23, 2006.
Afdhal NH, Freilich B, Levine R. Colchicine versus pegintron long-term (COPILOT) trial: interim analysis of clinical outcomes at year 2 [abstract]. Hepatology 2004, 40:238A.
Davis GL, Nelson DR, Terrault N, et al.: A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005, 11:941–949.
Chalasani N, Manzarbeitia C, Ferenci P, et al.: Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005, 41:289–298.
Shergill AK, Khalili M, Straley S, et al.: Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005, 5:118–124. Sole randomized trial of preemptive combination therapy. SVR was 18.0% with RBV, 2.5% without.
Sugawara Y, Makuuchi M, Matsui Y, et al.: Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004, 78:1308–1311.
A study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (ribavirin) administered after liver transplantation for hepatitis C (PHOENIX). Available at: www.clinicaltrials.gov/ct/gui/show/NCT00087633. Accessed June 15, 2006.
Samuel D, Bizollon T, Feray C, et al.: Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003, 124:642–650. The sole randomized trial of combination therapy in the setting of histologically evident post-transplantation HCV recurrence. EOTR and SVR rates were 32% and 21%, respectively, in the treatment group, with lack of EOTR and SVR in controls who received no antiviral therapy.
Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al.: Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002, 8:1000–1006.
Bizollon T, Ahmed SN, Radenne S, et al.: Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003, 52:283–287.
Berenguer M, Prieto M, Palau A, et al.: Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol 2004, 16:1207–1212.
Giostra E, Kullak-Ublick GA, Keller W, et al.: Ribavirin/ interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 2004, 17:169–176.
Mukherjee S, Lyden E, McCashland TM, Schafer DF: Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients. J Gastroenterol Hepatol 2005, 20:198–203.
Burra P, Targhetta S, Pevere S, et al.: Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience. Transplant Proc 2006, 38:1127–1130.
Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al.: Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002, 8:623–629.
Dumortier J, Scoazec JY, Chevallier P, Boillot O: Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004, 40:669–674.
Neff GW, Montalbano M, O’Brien CB, et al.: Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004, 78:1303–1307.
Rodriguez-Luna H, Khatib A, Sharma P, et al.: Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004, 77:190–194.
Castells L, Vargas V, Allende H, et al.: Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005, 43:53–59.
Heydtmann M, Freshwater D, Dudley T, et al.: Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. Am J Transplant 2006, 6:825–833.
Bizollon T, Adham M, Pradat P, et al.: Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C. Transplantation 2005, 79:325–329.
Smallwood GA, Davis L, Connor K, et al.: Nonresponders of interferon/ribavirin treatment for recurrent hepatitis C following liver transplantation. Transplant Proc 2003, 35:1476–1477.
Berenguer M, Prieto M, Palau A, et al.: Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006, 12:1067–1076.
Carmiel-Haggai M, Fiel MI, Gaddipati HC, et al.: Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl 2005, 11:1567–1573.
Walsh MJ, Jonsson JR, Richardson MM, et al.: Nonresponse to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006, 55:529–535.
Individualized dosing efficacy vs. flat dosing to assess optimal pegylated interferon therapy (Ideal Study). Available at: www.idealstudy.com. Accessed June 15, 2006.
Curry MP, Afdhal NH: Use of growth factors with antiviral therapy for chronic hepatitis C. Clin Liver Dis 2005, 9:439–451.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Everson, G.T., Kulig, C.C. Antiviral therapy for hepatitis C in the setting of liver transplantation. Curr Treat Options Gastro 9, 520–529 (2006). https://doi.org/10.1007/s11938-006-0008-5
Issue Date:
DOI: https://doi.org/10.1007/s11938-006-0008-5